HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Expression of immunoreactivity and genetic mutation in eosinophilic and ciliated metaplastic changes of endometrial glandular and stromal breakdown: cytodiagnostic implications.

Abstract
Various metaplastic changes may be present in endometrium, in which also cellular atypias may often be observed. Particularly, eosinophilic and ciliated changes (ECCs) occur in both nonneoplastic and neoplastic endometrium. This may cause confusion in the cytodiagnosis. This study was enterprised to investigate the possible help of immunocytochemical and cytogenetic study in the diagnostic and biologic assessment of ECC cells. In immunocytochemistry for p53 protein, Ki-67, and cyclin A, the material consists of 40 cases of cytologic smears examined by direct sampling of the endometrial cavity comprising 30 cases of ECC in endometrial glandular and stromal breakdown (EGBD) and 10 cases of well-differentiated adenocarcinoma (G1). After cytodiagnosis, immunostaining for p53 protein, Ki-67, and cyclin A was performed on multiple wet-fixed slides from each single case to evaluate the immunoreactivity, intensity of nuclear staining, and nuclear labeling index (N-LI). The intensity of nuclear staining was scored as negative (0), weak (1), moderate (2), or strong (3), and the N-LI was scored as less than 10% (0), from 10% to 25% (1), from 26% to 50% (2), or more than 50% (3), and the final score was calculated by adding both partial scores. A statistical significance test was performed by using Mann-Whitney U test, and the result was judged as significant when the P value was less than .05. For genetic mutation analysis of p53, the material comprised 6 cases of EGBD in which a high score was measured with immunocytochemistry for p53 protein, and the presence of ECC was confirmed on the hematoxylin and eosin. The ECC cells on paraffin-embedded specimens were captured using laser capture microdissection technology. Mutations in p53 gene (exons 5-8) were examined using DNA sequencing analysis. In immunocytochemistry for p53 protein, Ki-67, and cyclin A, the proportions of immunoreactive cells for p53 were statistically higher in ECC compared with those of G1 (P < .05). The proportions of the immunoreactive cells for Ki-67 and cyclin A were statistically higher in G1 compared with those of ECC (P < .05). (2) In genetic mutation analysis of p53, DNA sequencing of p53 in 6 cases revealed no mutations. The percentage of immunoreactive cells for p53 protein were higher in ECC than in G1, but the mutation point was not confirmed in genetic mutation analysis. The differential expression of these biologic parameters in ECC cells could be considered of possible relevance to the cytopathologic diagnosis in the future.
AuthorsKeiko Shimizu, Yoshiaki Norimatsu, Tadao K Kobayashi, Masami Sakurai, Seiko Ogura, Akihiko Yoshizawa, Tomoyuki Miyamoto, Yasuyuki Miyake, Yatsuki Aratake, Takuya Sakaguchi, Eiji Ohno
JournalAnnals of diagnostic pathology (Ann Diagn Pathol) Vol. 13 Issue 2 Pg. 89-95 (Apr 2009) ISSN: 1532-8198 [Electronic] United States
PMID19302956 (Publication Type: Journal Article)
Chemical References
  • Cyclin A
  • Ki-67 Antigen
  • Tumor Suppressor Protein p53
  • Eosine Yellowish-(YS)
Topics
  • Adenocarcinoma (genetics, metabolism, pathology)
  • Base Sequence
  • Cilia (pathology)
  • Cyclin A (biosynthesis)
  • Endometrial Neoplasms (genetics, metabolism, pathology)
  • Endometrium (metabolism, pathology)
  • Eosine Yellowish-(YS)
  • Female
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen (biosynthesis)
  • Lasers
  • Metaplasia
  • Microdissection
  • Molecular Sequence Data
  • Mutation
  • Tumor Suppressor Protein p53 (biosynthesis, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: